Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients

Summary

This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.

Conditions

• Aspirin
• Gastric Cancer

Interventions

DRUG

Aspirin 100mg

Daily aspirin 100 mg for 5 years

DRUG

Placebo oral tablet

Daily placebo for 5 years

Sponsors & Collaborators

• Incheon St.Mary's Hospital/The Catholic University

  collaborator UNKNOWN

• Kosin University Gospel Hospital

  collaborator OTHER

• Pusan National University Hospital

  collaborator OTHER

• SMG-SNU Boramae Medical Center

  collaborator OTHER

• Chonnam National University Hospital

  collaborator OTHER

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  collaborator OTHER

• Chilgok Kyungpook National University

  collaborator UNKNOWN

• Hallym University Medical Center

  collaborator OTHER

• Asan Medical Center

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Severance Hospital

  collaborator OTHER

• Samsung Medical Center

  collaborator OTHER

• National Cancer Center, Korea

  lead OTHER_GOV

Principal Investigators

• Il Ju Choi, M.D., Ph.D. · National Cancer Center, Korea

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

19 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-02-15

Primary Completion

2031-03-31

Completion

2032-03-31

Countries

• South Korea

Study Locations